Commercial revenue increased 17% to $13.9 million, while international revenue reached a record $12.6 million, up 22% from the prior-year period. Cingal revenue rose 32% year over year and Monovisc revenue increased 24%, together adding approximately $2 million of incremental profitable revenue during the period. Anika raised its full-year outlook as follows:Total company revenue growth of 5% to 10%, up from prior guidance of 1% to 9%. OEM revenue growth of 0% to 5%, compared with prior expectations of a 5% decline to flat performance. About Anika Therapeutics (NASDAQ:ANIK)Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products.